NEW YORK (
) is trading at unusually high volume Tuesday with 1.6 million shares changing hands. It is currently at four times its average daily volume and trading up 79 cents (+10.7%) at $8.20 as of 3:48 p.m. ET.
Neurocrine has a market cap of $409 million and is part of the
industry. Shares are down 3% year to date as of the close of trading on Friday.
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company has a P/E ratio of 82.3, below the average drugs industry P/E ratio of 105.9 and above the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Neurocrine as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. You can view the full
See all heavy volume stocks in our
or get investment ideas from our
Interested in other stocks that are rising on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting
to 95370 or select from